Kate Rosenbluth
About Kate Rosenbluth
Kate Rosenbluth Title
Kate Rosenbluth holds the position of Co-President at Cala Health, a company she founded to address the challenge of providing non-surgical therapy for hand tremors. As an expert in the field, her leadership guides the development and implementation of innovative solutions for movement disorders.
Founding of Cala Health
In 2014, Kate Rosenbluth founded Cala Health with the goal of developing non-surgical therapies for hand tremors. By 2015, she co-founded Cala Health with Scott Delp and secured Series A funding aimed at treating movement disorders using biologic signatures customized to each patient's unique tremor signature. Under her leadership, Cala Health aims to revolutionize the treatment of movement disorders.
Neuroscience and Neurosurgery Experience
Kate Rosenbluth has an extensive background in neuroscience and neurosurgery, having worked at UCSF in the Bankiewicz lab. Her work included research on gene therapy and Deep Brain Stimulation (DBS) for Parkinson's disease. This experience provided her with critical insights and expertise that she later applied to her work at Cala Health.
Stanford Biodesign Fellowship
Kate Rosenbluth was a Biodesign fellow at Stanford Hospitals and Clinics. During this time, she identified the significant burden and unmet need within Essential Tremor (ET) through clinical observations. This fellowship played a pivotal role in shaping her innovative approach to developing therapies for movement disorders.
Cala Health Milestones
Under Kate Rosenbluth's leadership, Cala Health has achieved several key milestones. In April 2018, Cala Health received FDA de novo clearance for Cala One therapy for temporary relief of hand tremors in adults with Essential Tremor (ET). In December 2019, they completed the PROSPECT study, the largest noninvasive therapeutic clinical research study ever conducted for ET. Additionally, in October 2020, Cala Health obtained FDA Breakthrough Device Designation for Cala TAPS therapy to treat action tremors in Parkinson's disease. Most recently, in April 2023, they introduced the next-generation device, Cala kIQ, at the American Academy of Neurology meeting.